Radius Health (NASDAQ:RDUS) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Thursday.

Other analysts have also issued research reports about the stock. BidaskClub upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Morgan Stanley upped their target price on shares of Radius Health from $57.00 to $61.00 and gave the stock an “overweight” rating in a research note on Friday, March 2nd. Cantor Fitzgerald set a $58.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research note on Thursday, March 22nd. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Finally, Leerink Swann assumed coverage on shares of Radius Health in a research note on Thursday, March 29th. They issued an “outperform” rating and a $53.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the company. Radius Health presently has an average rating of “Hold” and a consensus price target of $52.10.

Radius Health stock opened at $31.51 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.96 and a current ratio of 5.04. Radius Health has a 12-month low of $24.66 and a 12-month high of $49.16. The firm has a market cap of $1,492.01, a P/E ratio of -5.43 and a beta of 1.25.

Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.43) by ($0.16). The company had revenue of $7.66 million for the quarter, compared to the consensus estimate of $7.37 million. During the same quarter in the previous year, the firm earned ($1.22) EPS. The firm’s revenue for the quarter was up 666.0% compared to the same quarter last year. equities research analysts expect that Radius Health will post -5.11 EPS for the current fiscal year.

In other news, major shareholder Growth N. V. Biotech purchased 40,000 shares of the stock in a transaction dated Thursday, April 19th. The shares were purchased at an average cost of $33.80 per share, with a total value of $1,352,000.00. Following the completion of the acquisition, the insider now owns 6,050,913 shares in the company, valued at approximately $204,520,859.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Growth N. V. Biotech purchased 80,000 shares of the stock in a transaction dated Friday, March 2nd. The stock was purchased at an average cost of $32.52 per share, for a total transaction of $2,601,600.00. Following the completion of the acquisition, the insider now owns 5,853,799 shares of the company’s stock, valued at approximately $190,365,543.48. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 245,000 shares of company stock worth $8,361,100. Insiders own 15.00% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Eversept Partners LLC bought a new position in Radius Health during the fourth quarter valued at approximately $6,179,000. Prosight Management LP bought a new position in Radius Health during the fourth quarter valued at approximately $3,495,000. Mutual of America Capital Management LLC grew its position in Radius Health by 45.6% during the fourth quarter. Mutual of America Capital Management LLC now owns 49,615 shares of the biopharmaceutical company’s stock valued at $1,576,000 after acquiring an additional 15,534 shares during the last quarter. Teacher Retirement System of Texas bought a new position in Radius Health during the fourth quarter valued at approximately $353,000. Finally, Consonance Capital Management LP bought a new position in Radius Health during the fourth quarter valued at approximately $84,168,000.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.